Authors
Andreas Du Bois, Anne Floquet, Jae-Weon Kim, Joern Rau, Josep M Del Campo, Michael Friedlander, Sandro Pignata, Keiichi Fujiwara, Ignace Vergote, Nicoletta Colombo, Mansoor R Mirza, Bradley J Monk, Rainer Kimmig, Isabelle Ray-Coquard, Rongyu Zang, Ivan Diaz-Padilla, Klaus H Baumann, Marie-Ange Mouret-Reynier, Jae-Hoon Kim, Christian Kurzeder, Anne Lesoin, Paul Vasey, Christian Marth, Ulrich Canzler, Giovanni Scambia, Muneaki Shimada, Paula Calvert, Eric Pujade-Lauraine, Byoung-Gie Kim, Thomas J Herzog, Ionel Mitrica, Carmen Schade-Brittinger, Qiong Wang, Rocco Crescenzo, Philipp Harter
Publication date
2014/10/20
Journal
Journal of clinical oncology
Volume
32
Issue
30
Pages
3374-3382
Publisher
American Society of Clinical Oncology
Description
Purpose
Pazopanib is an oral, multikinase inhibitor of vascular endothelial growth factor receptor (VEGFR) -1/-2/-3, platelet-derived growth factor receptor (PDGFR) -α/-β, and c-Kit. Preclinical and clinical studies support VEGFR and PDGFR as targets for advanced ovarian cancer treatment. This study evaluated the role of pazopanib maintenance therapy in patients with ovarian cancer whose disease did not progress during first-line chemotherapy.
Patients and Methods
Nine hundred forty patients with histologically confirmed cancer of the ovary, fallopian tube, or peritoneum, International Federation Gynecology Obstetrics (FIGO) stages II-IV, no evidence of progression after primary therapy consisting of surgery and at least five cycles of platinum-taxane chemotherapy were randomized 1:1 to receive pazopanib 800 mg once per day or placebo for up to 24 months. The primary end point was progression-free …
Scholar articles
A Du Bois, A Floquet, JW Kim, J Rau, JM Del Campo… - Journal of clinical oncology, 2014